SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 648.55+0.2%2:15 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Biotechwantabe6/30/2021 12:25:51 PM
1 Recommendation

Recommended By
CuttingEdge Bio

  Read Replies (1) of 3557
 
Guggenheim Biopharma Strategy Series | Biopharma’s Next Decade: Views from the Top on Global Strategy and Innovation

Regeneron partners are doing well: ntla and alny. Might be dragging regeneron up; but, regeneron is probably contributing with their slow but steady progress.

Time for a Tesla happy dance - re ntla.

I still think regeneron is undervalued.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News